NCT03366428: Phase 1 Study of DS-8201a in HER-2 Breast Cancer Patients

NCT03366428
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03366428

Comments are closed.

Up ↑